SSA
MLTX icon

Schonfeld Strategic Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Sell
27,575
-1,107
-4% -$20.1K ﹤0.01% 1783
2026
Q1 		$535K Sell
28,682
-293,579
-91% -$4.86M ﹤0.01% 1355
2025
Q4 		$4.25M Sell
322,261
-643,144
-67% -$7.59M 0.02% 599
2025
Q3 		$6.92M Buy
+965,405
New +$50.3M 0.04% 463
2025
Q2 		– Sell
-10,669
Closed -$417K – 2349
2025
Q1 		$417K Buy
10,669
+6,758
+173% +$291K ﹤0.01% 1658
2024
Q4 		$212K Sell
3,911
-82,864
-95% -$4.23M ﹤0.01% 1746
2024
Q3 		$4.38M Sell
86,775
-29,663
-25% -$1.39M 0.03% 594
2024
Q2 		$5.12M Sell
116,438
-27,012
-19% -$1.14M 0.03% 545
2024
Q1 		$7.21M Sell
143,450
-16,950
-11% -$919K 0.05% 500
2023
Q4 		$9.69M Sell
160,400
-180,300
-53% -$9.29M 0.06% 361
2023
Q3 		$19.4M Buy
340,700
+222,740
+189% +$12.3M 0.15% 189
2023
Q2 		$6.02M Buy
117,960
+80,760
+217% +$2.17M 0.05% 447
2023
Q1 		$796K Buy
+37,200
New +$625K 0.01% 1028
2022
Q1 		– Sell
-50,106
Closed -$496K – 2788
2021
Q4 		$496K Buy
+50,106
New +$498K ﹤0.01% 1268

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Schonfeld Strategic Advisors's MLTX Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 3.9% in Q2 2026, selling an estimated $20.1K and leaving 27,575 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

Schonfeld Strategic Advisors first reported a position in MLTX in Q4 2021 and has held it in 14 quarters since. The position peaked at $19.4M in Q3 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Schonfeld Strategic Advisors held 27,575 shares of MoonLake Immunotherapeutics worth $537K as of Q2 2026.
  • Schonfeld Strategic Advisors sold 1,107 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $20.1K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1783 holding.
  • Schonfeld Strategic Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 14 quarters since.
  • Schonfeld Strategic Advisors's MoonLake Immunotherapeutics position peaked at $19.4M in Q3 2023.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.